The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!
13
Jan
Jan
The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!
07
Jan
Jan
The New Year is an exciting time as we all focus on goals and resolutions. At HEMEX, we are focused on bringing you solutions at each critical step of the clinical development of your product. Together we can generate the accurate evidence needed for success!
30
Dec
Dec
This year has been unlike any other, but at HEMEX we have continued with a positive spirit through it all. In this article, we want to take a look back at 2020 as we look ahead to all that we can accomplish next year.
2020 has turned our lives upside down. It started as an exciting yea
Collaboration, Competitions, Innovation
Sleepiz is one of the winners of the 23rd annual IMD Startup Competition
18
Dec
Dec
In times of high uncertainty like this 2020 year, it is necessary to celebrate and savor the victories. We want to congratulate our portfolio company Sleepiz for its well-deserved success in winning collaboration with one of the three Executive MBA cohorts at the beginning of 2021
Awarenesss, Clinical Development, Funding, Innovation
It’s Time For The Next-Generation Gentle and Modern Gynecology
11
Dec
Dec
Our portfolio company Aspivix is developing a technology based on a new approach to replace the cervical tenaculum used in the Intra-Uterine device insertion – which is very painful – with a gentle vacuum suction-based device that guarantees no trauma or bleeding. The Intra-Uterine device (IUD) is the most cost-effective reversible contraception method available […]
Funding, Innovation, Press Release
Annaida Technologies: Providing The Technology To Measure The Inaccessible
03
Dec
Dec
Our portfolio company Annaida is developing a medical device that will allow doctors to screen embryos and determine the most viable to increase chances of success. Their technology can be used to detect and quantify various chemical compounds in microscopic entities, such as human embryos or stem cells, in a non-invasive way. Annaida Technologies […]
25
Nov
Nov
Big congrats to our portfolio company Sedimentum, which has achieved several milestones this year! Among others, they have closed their pre-seed financing round, launched several proof-of-concept studies, their CEO got listed in the Forbes 30 under 30 list, and they have recently won the “Zuger Young Entrepreneur Award 2020.” What this fast-growing start-up has […]
Funding, Innovation
Juvabis Announces Positive Phase 1 Results of EBL-1003 in the Innovative Medicines Initiative’s ENABLE Consortium
24
Nov
Nov
Our portfolio company Juvabis AG announces the completion and positive results from its first-in-human single intravenous dose Phase 1 study in healthy volunteers. EBL-1003 (apramycin) was safe and well-tolerated in all dose groups. The results support further clinical development of EBL-1003 in patients. Juvabis AG is a clinical-stage biopharmaceutical company focused on discovering and […]